Paraskevas Tsaplaris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paraskevas Tsaplaris has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Athanasios Makris
Arrhythmia Unit Onassis Cardiac Surgery Center Athens Greece
1 shared publication - Athanasios Saplaouras
Arrhythmia Unit Onassis Cardiac Surgery Center Athens Greece
1 shared publication Athina Goliopoulou
3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece
1 shared publicationCostas Tsioufis
1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece
1 shared publication- Dimitris Tousoulis
First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece
1 shared publication Efstratios Katsianos
3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece
1 shared publication
Latest Publications
- 27 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Capture Verification in Left Bundle Branch Area Pacing: Reporting Gaps and a Practical Framework
Background: Left bundle branch area pacing (LBBAP) comprises two physiologically distinct interventions: left bundle branch pacing (LBBP), which captures the conduction system, and left ventricular septal pacing (LVSP), which captures septal myocardium only. How consistently studies document which was achieved is unknown. Methods: We searched PubMed/MEDLINE, Europe PMC, and OpenAlex to June 21, 2026, and audited the eligible studies against ten prespecified reporting items, four primary and six supporting. Screening and extraction were independent and in duplicate. A continuous 0–100 score, threshold sensitivity analyses, and stratification were post hoc. Results: An explicit capture definition was reported in 43 of 46 studies (93%), a numerator with denominator in 32 (70%), and outcomes by capture status in 18 (39%). LBBP, LVSP, and indeterminate capture were separated in one study (2%). Independent adjudication was described in two (4%), follow‐up reassessment in seven (15%), and programmed output in three (7%). No study reported all four primary items with at least four supporting items; the median score was 43.3. Across seven alternative thresholds, six studies (13%) qualified at most. Studies from 2024 to 2026 scored higher than those from 2020 to 2023 (median 55.0 vs. 36.7; p = 0.015), although reporting of adjudication did not improve and reporting of reassessment only marginally. These comparisons were exploratory and unadjusted for multiplicity. Conclusions: In LBBAP studies with extractable capture information, capture verification is reported inconsistently and is often not separated from procedural success. We propose a reporting framework and an exploratory, author‐derived capture‐confidence score.
- 27 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Capture Verification in Left Bundle Branch Area Pacing: Reporting Gaps and a Practical Framework
Background: Left bundle branch area pacing (LBBAP) comprises two physiologically distinct interventions: left bundle branch pacing (LBBP), which captures the conduction system, and left ventricular septal pacing (LVSP), which captures septal myocardium only. How consistently studies document which was achieved is unknown. Methods: We searched PubMed/MEDLINE, Europe PMC, and OpenAlex to June 21, 2026, and audited the eligible studies against ten prespecified reporting items, four primary and six supporting. Screening and extraction were independent and in duplicate. A continuous 0–100 score, threshold sensitivity analyses, and stratification were post hoc. Results: An explicit capture definition was reported in 43 of 46 studies (93%), a numerator with denominator in 32 (70%), and outcomes by capture status in 18 (39%). LBBP, LVSP, and indeterminate capture were separated in one study (2%). Independent adjudication was described in two (4%), follow‐up reassessment in seven (15%), and programmed output in three (7%). No study reported all four primary items with at least four supporting items; the median score was 43.3. Across seven alternative thresholds, six studies (13%) qualified at most. Studies from 2024 to 2026 scored higher than those from 2020 to 2023 (median 55.0 vs. 36.7; p = 0.015), although reporting of adjudication did not improve and reporting of reassessment only marginally. These comparisons were exploratory and unadjusted for multiplicity. Conclusions: In LBBAP studies with extractable capture information, capture verification is reported inconsistently and is often not separated from procedural success. We propose a reporting framework and an exploratory, author‐derived capture‐confidence score.
- 1 June 2022
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 29 (21) , 3790-3805
The Role of Endothelial Related Circulating Biomarkers in COVID-19. A Systematic Review and Meta-analysis
Background: Several studies have revealed the link between Coronavirus Disease 2019 (COVID-19) and endothelial dysfunction. To better understand the global pattern of this relationship, we conducted a meta-analysis on endothelial biomarkers related to COVID-19 severity. Methods: We systematically searched the literature up to March 10, 2021, for studies investigating the association between COVID-19 severity and the following endothelial biomarkers: Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), E-selectin, P-selectin, Von Willebrand Factor Antigen (VWF-Ag), soluble Thrombomodulin (sTM), Mid-regional pro-adrenomedullin (MR-proADM), and Angiopoietin-2 (Ang-2). Pooled estimates and mean differences (PMD) for each biomarker were reported. Results: A total of 27 studies (n=2213 patients) were included. Critically ill patients presented with higher levels of MR-proADM (PMD: 0.71 nmol/L, 95% CI: 0.22 to 1.20 nmol/L, p=0.02), E-selectin (PMD: 13,32 pg/ml, 95% CI: 4,89 to 21,75 pg/ml, p=0.008), VCAM-1 (PMD: 479 ng/ml, 95% CI: 64 to 896 ng/ml, p=0.03), VWF-Ag (PMD: 110.5 IU/dl, 95% CI: 44.8 to 176.1 IU/dl, p=0.04) and Ang-2 (PMD: 2388 pg/ml, 95% CI: 1121 to 3655 pg/ml, p=0.003), as compared to non-critically ill ones. ICAM-1, P-selectin and thrombomodulin did not differ between the two groups (p>0.05). Conclusion: Endothelial biomarkers display significant heterogeneity in COVID-19 patients, with higher MR-proADM, E-selectin, VCAM-1, VWF-Ag, and Ang-2 levels being associated with increased severity. These findings strengthen the evidence on the key role of endothelial dysfunction in disease progress.
- 1 June 2022
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 29 (21) , 3790-3805
The Role of Endothelial Related Circulating Biomarkers in COVID-19. A Systematic Review and Meta-analysis
Background: Several studies have revealed the link between Coronavirus Disease 2019 (COVID-19) and endothelial dysfunction. To better understand the global pattern of this relationship, we conducted a meta-analysis on endothelial biomarkers related to COVID-19 severity. Methods: We systematically searched the literature up to March 10, 2021, for studies investigating the association between COVID-19 severity and the following endothelial biomarkers: Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), E-selectin, P-selectin, Von Willebrand Factor Antigen (VWF-Ag), soluble Thrombomodulin (sTM), Mid-regional pro-adrenomedullin (MR-proADM), and Angiopoietin-2 (Ang-2). Pooled estimates and mean differences (PMD) for each biomarker were reported. Results: A total of 27 studies (n=2213 patients) were included. Critically ill patients presented with higher levels of MR-proADM (PMD: 0.71 nmol/L, 95% CI: 0.22 to 1.20 nmol/L, p=0.02), E-selectin (PMD: 13,32 pg/ml, 95% CI: 4,89 to 21,75 pg/ml, p=0.008), VCAM-1 (PMD: 479 ng/ml, 95% CI: 64 to 896 ng/ml, p=0.03), VWF-Ag (PMD: 110.5 IU/dl, 95% CI: 44.8 to 176.1 IU/dl, p=0.04) and Ang-2 (PMD: 2388 pg/ml, 95% CI: 1121 to 3655 pg/ml, p=0.003), as compared to non-critically ill ones. ICAM-1, P-selectin and thrombomodulin did not differ between the two groups (p>0.05). Conclusion: Endothelial biomarkers display significant heterogeneity in COVID-19 patients, with higher MR-proADM, E-selectin, VCAM-1, VWF-Ag, and Ang-2 levels being associated with increased severity. These findings strengthen the evidence on the key role of endothelial dysfunction in disease progress.